Omeros (NASDAQ:OMER) Hits New 12-Month High – Time to Buy?

Shares of Omeros Corporation (NASDAQ:OMER) hit a new 52-week high on Thursday . The stock traded as high as $17.65 and last traded at $15.0850, with a volume of 24509175 shares traded. The stock had previously closed at $8.75.

Key Stores Impacting Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: FDA approval of YARTEMLEA — the first and only approved lectin‑pathway inhibitor for TA‑TMA, giving Omeros an immediate commercial product and a clear revenue path. Business Wire Release
• Positive Sentiment: Broad media and analyst lift — multiple outlets and analysts framed the approval as transformative, noting longer‑term upside as Omeros commercializes YARTEMLEA. Coverage likely accelerated retail buying. Seeking Alpha
• Positive Sentiment: Analyst support and price targets — sell‑side firms reiterated Buy ratings and new/upgraded targets (examples: D. Boral Capital $36 PT; H.C. Wainwright $20 PT), giving investors headline upside scenarios. TipRanks
• Positive Sentiment: Retail and options activity — unusually high call buying (large blocks of calls) and a surge in volume/retail interest compounded buying pressure and volatility. MSN coverage
• Neutral Sentiment: Short‑interest report appears inconsistent/zero in the data feed (days‑to‑cover shows 0.0), so short‑covering impact is unclear from published figures.
• Neutral Sentiment: Trading halts (news‑pending and LULD pause) occurred as volume spiked; halts reflect high volatility and information flow but are procedural rather than fundamental.
• Negative Sentiment: Execution and revenue risk remain — Omeros is still building commercial infrastructure, the TA‑TMA population is small/rare (limiting near‑term sales), and the company remains unprofitable, so post‑approval pricing, uptake and margins will determine sustainable upside.

Analysts Set New Price Targets

OMER has been the subject of a number of research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Wednesday, October 15th. HC Wainwright restated a “buy” rating on shares of Omeros in a report on Wednesday. Wall Street Zen raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. D. Boral Capital reissued a “buy” rating and set a $36.00 price objective on shares of Omeros in a report on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.67.

Omeros Stock Up 72.4%

The stock has a 50-day moving average of $8.81 and a 200 day moving average of $5.66. The stock has a market cap of $1.07 billion, a PE ratio of -7.47 and a beta of 2.48.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.39. On average, equities analysts anticipate that Omeros Corporation will post -3.09 EPS for the current year.

Institutional Trading of Omeros

Hedge funds and other institutional investors have recently bought and sold shares of the stock. B. Riley Wealth Advisors Inc. purchased a new stake in Omeros in the 2nd quarter worth approximately $32,000. Harbour Investments Inc. boosted its holdings in Omeros by 46.1% during the second quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 4,251 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Omeros by 829.6% during the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 11,971 shares during the period. Sei Investments Co. purchased a new position in Omeros in the second quarter valued at $40,000. Finally, Russell Investments Group Ltd. raised its position in shares of Omeros by 113.1% in the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 5,677 shares during the period. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.